Introduction
============

Human immunodeficiency virus (HIV) and hepatitis C virus share the same mode of transmission (through direct blood to blood contact), and therefore, the incidence of coinfection in Italy is extremely high, reaching a peak of 45% as reported by Italian Cohort Naive Antiretrovirals foundation in 2002.[@b1-ceor-8-015] This issue is largely due to the high percentage of former drug users among Italian people living with HIV.[@b1-ceor-8-015]

The most recent guidelines from the European Liver Association do not make any distinction between mono or coinfected patients[@b2-ceor-8-015] for the treatment with anti-HCV directly active antivirals. On the other hand, it is generally accepted that in HIV/HCV patients there is faster progression toward cirrhosis and hepatocellular carcinoma (HCC) than in mono-infected.[@b3-ceor-8-015]--[@b11-ceor-8-015]

Several study cohorts have shown the natural history of end-stage liver disease in HIV/HCV-coinfected patients.[@b12-ceor-8-015]--[@b14-ceor-8-015] In addition, the natural history of compensated cirrhosis in coinfected patients has been described in smaller cohorts of less than 200 patients.[@b15-ceor-8-015],[@b16-ceor-8-015] Moreover in HIV/HCV coinfection, SVR may also decrease the progression of HIV infection and mortality not related to liver disease.[@b17-ceor-8-015],[@b18-ceor-8-015]

The clinical benefits associated with the eradication of HCV have been well characterized in patients with advanced fibrosis or cirrhosis but not in patients with less advanced stages of liver fibrosis. Also, a comprehensive costs--opportunity evaluation in patients with a less severe disease is missing. This is a relevant question, particularly in HIV/HCV-coinfected patients, for whom the delivery of effective HCV treatment could be a priority even in mild to moderate stages of liver fibrosis, in order to prevent a more rapid disease progression. Based on hospital databases, in Liguria region one out of three HIV patients is coinfected with HCV; in addition, Liguria has the highest prevalence of AIDS among other regions in Italy.[@b19-ceor-8-015] Chronic HCV in Italy is also a leading cause of infectious admissions in hospital for HIV patients.[@b20-ceor-8-015] Therefore, earlier treatment in this population is crucial in terms of clinical benefits, prevention of disease progression and HCV-related health care direct costs limitation.[@b21-ceor-8-015] Sofosbuvir (SOF) is a pan-genotypic drug which can be combined with other agents like ribavirin, simeprevir, daclatasvir or, in single-tablet regimen, together with ledipasvir as all oral treatment for HCV, with different entry price levels paid and reimbursed by the National Health Service.

Also, SOF and sofosbuvir/ledipasvir are linked to a price/volume payback scheme covered by a secrecy agreement[@b22-ceor-8-015] that, in practice, affects regimen's cost variations. Due to budget constraints, as of year 2015, the national registration in terms of reimbursement of such regimens has been restricted to patients with more severe stages of disease, according to ethical and clinical considerations.[@b23-ceor-8-015]--[@b26-ceor-8-015] But, we may expect in the near future costs declining, according to new price negotiations that try to include patients with less severe conditions to be eligible to reimbursement by National Health Authorities.

Therefore, we tried to assess a 5-year horizon budget impact (ie, the Regional Health System Management's term) and cost saving analysis related to the effects of SVR after treatment with SOF regimens on mortality and liver related complications in HIV/HCV-coinfected patients in any disease stage.

Patients and methods
====================

Model structure
---------------

A Markov model has been applied to conduct a multicenter, 5-year horizon prospective costs evaluation, involving four Italian Infectious Diseases Departments (Galliera, San Martino, Sanremo, and La Spezia) in Liguria region, Italy. In all, 1,005 all genotypes adult HIV/HCV patients, under observation by clinicians as of May 2015, were included in the analysis. The patients' characteristics in the group of pooled data were classified according to their current disease stage: non cirrhotics, cirrhotics, HCC, and transplants ([Table 1](#t1-ceor-8-015){ref-type="table"}).

On completion of treatment (at 12 or 24 weeks), patients who achieve SVR are considered to be permanently cured of the infection (SVR at 12 weeks has been set as an appropriate endpoint for regulatory approval and is accepted by most clinical and regulatory authorities).[@b27-ceor-8-015] Patients who do not achieve SVR progress to more advanced stages of the disease. In this case, transition probabilities and disease progression rates are based both on literature and clinical experts' opinion. All cause mortality rates were applied to all health states in the model.

The cycle length was 3 months to account for the 12-week treatment duration for some SOF-based regimens, costs and outcomes were discounted at 3% as recommended by the Italian Association of Health Economics.[@b28-ceor-8-015] All data were anonymously processed and analyzed. The comparison of 1) "no treatment" disease progression costs vs 2) the economic impact of SOF-based regimens was investigated.

This study was developed with the data available inside the IANUA study (Indagine sull'appropiatezza prescrittiva degli antiretrovirali antiretrovirali) which was approved by Comitato Etico Regione Liguria, with provision number PR 032 REG2014, obtained on 08 April, 2014.

Efficacy: SVR rates
-------------------

The SVR rates of SOF-based regimens for each patient disease stage were derived from trials and literature[@b29-ceor-8-015]--[@b33-ceor-8-015] and validated by expert opinion. The average SVR success rate for SOF-based regimens included in the model was 90%.

Transition probabilities
------------------------

Transition probabilities in the analysis related to HCV progression from one disease stage to another were taken from the literature[@b17-ceor-8-015],[@b34-ceor-8-015]--[@b37-ceor-8-015] ([Table 2](#t2-ceor-8-015){ref-type="table"}); where this was not possible, we obtained them from expert opinion. These estimates were converted to annual probabilities for the analysis.

Resource consumption and costs
------------------------------

In this study, cost data were analyzed from the Regional Health Service point of view. Costs associated with each health state were obtained from the White Paper by the Italian Association of the Study of the Liver[@b38-ceor-8-015] and the COME Study,[@b21-ceor-8-015] which are aligned with the costs for each health state resulting from the Ospedale Galliera budgeting system (which is a component of Italian Network for Standard Costs in Healthcare). As part of the reimbursement agreement with the Italian reimbursement agency, we assumed that 24 weeks of treatment with SOF had the same price as 12 weeks of treatment. Drug prices (VAT included) for all the regimens used in the analysis are those applied to the Italian NHS hospital pharmacies ([Table 3](#t3-ceor-8-015){ref-type="table"}).

Sensitivity analysis
--------------------

The sensitivity analysis verified the impact of a series of variations of the base case with a large influence on the obtained results. A series of univariate analyses was carried out on some parameters of the simulation model, such as SVR rates, anti-HCV cost regime, and mortality rate. Each parameter was varied with ±10% with respect to the base-case scenario on the basis of Italian guidelines on economic evaluation.[@b24-ceor-8-015]

Results
=======

[Table 4](#t4-ceor-8-015){ref-type="table"} shows the main results. In the "disease progression" scenario, over the next 5 years, the disease progression without treatments resulted in €54 million ca costs and 89 deaths. On the other hand, treatment containing SOF would save 68 people from HCV-related deaths. Overall, the SOF-based regimens with an average price \>€50,000 do not offer a favorable cost saving profile, as this cost generates more than €56 million expense. Moreover, when the average price of an SOF regimen varies from €45,000 to €15,000 the budget impact ranges from €50 to €20 million ca, ie, saving from 6% to 53% of liver-related disease management costs, respectively (min: 3.5€M--max: 34.1€ M ca). At the average price of €12,000, SOF-based regimens' expense was €17 million ca, saving 68% (€37 million ca) of costs compared with the disease progression scenario.

This result indicates that at this price level, the economic resources invested to treat from mild to moderate fibrosis stage patients are equal to the amount of direct costs of disease management in this stage, resulting in a convenient return of investment in the short term. The sensitivity analysis carried out on the main variables does not highlight significant variations with respect to the base case ([Table 5](#t5-ceor-8-015){ref-type="table"}).

Discussion
==========

The use of SOF regimens substantially reduces the clinical burden of HCV disease. We decided to focus on SOF-based regimens because, today, it is the only pan-genotypic drug (backbone) available. Although several studies reported that SOF therapies are cost-effective,[@b39-ceor-8-015]--[@b44-ceor-8-015] the resources needed to treat a large number of patients with HCV/HIV infection could be challenging for the Regional Healthcare System. On the other hand, an average SOF-based regimen price that starts descending progressively from the level of €45,000 would save direct costs optimizing economic resources and bringing a return on investments in the midterm, at the same time. SOF and sofosbuvir/ledipasvir joint reimbursed agreement is affected by a price/volume scheme leading to incremental economic payback when patient thresholds are achieved.[@b45-ceor-8-015] In fact as stated in the National Drug Agency (AIFA) resolution published,[@b46-ceor-8-015] Liguria region received its first amount of payback related to the usage of SOF-based regimens of €0.7 million starting to show benefit from the cost reduction. Therefore, it is reasonable to assume that in the near future the real average cost of SOF-based regimens will be lower than the initial entry prices. Finally, the agreement signed between the company and the AIFA lasts 18 months[@b47-ceor-8-015],[@b48-ceor-8-015] as a consequence it will expire by mid-2016 leading to a new price negotiation. To our knowledge, this is the first study that evaluates the budget impact of SOF-based regimens for HIV/HCV-coinfected patients in Italy.

Our study presents some limitations. First, clinical disease progression and SVR rates included in our analysis by clinicians may differ in clinical practice; therefore, our study used only the best available evidence on treatment efficacy for this population. Moreover, this analysis assumed that the achievement of SVR was equivalent to a permanent cure of patients, which could overestimate the benefits of therapies. In addition, additional potential costs of failures related to adverse events and interactions were not calculated. We also did not include the future possibility of re-treatment with next generation of antiviral agents because of a lack of data at the time of this evaluation. A much more comprehensive evaluation may consider budget impact including new unknown mono-infected patients that may emerge through awareness campaigns aiming to eradicate the disease. This data showing the reduction of coinfection of HIV/HCV is a clear sign that in a five year period the target population could not increase.[@b49-ceor-8-015] Finally, this analysis was focused just on the HCV issues of such patients; additional HIV drugs expense and related direct costs management were not considered but should be included by the Regional Healthcare System at the time of a comprehensive economic budget planning.

Conclusion
==========

Given the high rates of SVR these results suggested that, in the Italian Healthcare System, SOF-based regimens' price is a determinant and a predictor of the overall cost for the HCV management. At the average price per therapy of €12,000 over the next 5 years, SOF-based regimens are highly sustainable for the Healthcare System saving several million Euro of economic resource money needed to manage HCV in the HIV-coinfected population.
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###### 

HIV/HCV-coinfected patients[\*](#tfn1-ceor-8-015){ref-type="table-fn"} under observation in four Ligurian hospitals (Galliera, San Martino, Sanremo, and La Spezia, as of May 2015)

                              Fibrosis stage   N
  --------------------------- ---------------- -------
  Chronic hepatitis C (CHC)   F0--F2           528
                              F3               174
  Liver cirrhosis             F4               288
  HCC                                          15
  Total                                        1,005

**Note:**

Nine patients underwent liver transplantation.

**Abbreviations:** HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human immunodeficiency virus.

###### 

Transition probabilities: expected progression rates in 5 years (without treatment intervention)

  Year 0                          Year 5                    Probabilities   Source
  ------------------------------- ------------------------- --------------- ---------------------------------
  Non-cirrhotic, HIV-coinfected                             Base case: 0    Benhamou et al[@b7-ceor-8-015]
                                  Compensated cirrhosis     5 years: 0.05   
                                  Decompensated cirrhosis   5 years: 0.06   
                                  HCC                       5 years: 0.06   
                                  Liver transplant          5 years: 0.04   
                                  Death                     5 years: 0.06   
  Compensated cirrhosis                                     Base case: 0    
                                  Decompensated cirrhosis   5 years: 0.15   Fattovich et al[@b8-ceor-8-015]
                                  HCC                       5 years: 0.12   
                                  Liver transplant          5 years: 0.12   Fattovich et al[@b9-ceor-8-015]
                                  Death                     5 years: 0.10   
  Decompensated cirrhosis                                   Base case: 0    Pineda et al[@b12-ceor-8-015]
                                  HCC                       5 years: 0.12   
                                  Liver transplant          5 years: 0.12   
                                  Death                     5 years: 0.10   
  HCC                                                       Base case: 0    
                                  Death                     5 years: 0.4    
                                  Liver transplant          5 years: 0.5    Expert opinion
  Pre-OLT/Post-OLT                                          Base case: 0    
                                  Death, Year 3             5 years: 0.5    Clinical observation

**Note:** The probabilities show the probability for each single patient to progress from the conditions shown in Year 0 to each single condition by 5 year.

**Abbreviations:** OLT, liver transplant; HCC, hepatocellular carcinoma; HIV, human immunodeficiency virus.

###### 

SOF-based regimens' treatment prices (VAT included)

  Treatment regimen       Treatment prices (€) (≥12 weeks)
  ----------------------- ----------------------------------
  SOF + LDV (8 weeks)     29,810
  SOF + LDV               44,770
  SOF + SMV               57,200
  SOF + DCV (60 mg/die)   59,400
  SOF + DCV (90 mg/die)   78,100

**Abbreviations:** SOF, sofosbuvir; DCV, daclatasvir; LDV, ledispavir; SMV, simeprevir; mg/die, mg a day.

###### 

Results: disease stage costs (€) of disease progression scenario vs costs of SOF-based regimen scenarios (5-year horizon) for HIV/HCV-coinfected patients

  Scenario                  Average cost (€)   CHC          Cirrhosis    HCC         Transplant   Total        Diff vs Dis Progr   N of deaths
  ------------------------- ------------------ ------------ ------------ ----------- ------------ ------------ ------------------- -------------
  Disease progression                          9,347,851    8,433,814    3,364,394   33,260,750   54,406,809                       89
   SOF-based regimen no 1   12,000             9,358,785    3,877,691    516,439     3,506,075    17,258,990   −37,147,819         
   SOF-based regimen no 2   15,000             11,464,785   4,741,691    561,439     3,551,075    20,318,990   −34,087,819         
   SOF-based regimen no 3   20,000             14,974,785   6,181,691    636,439     3,626,075    25,418,990   −28,987,819         
   SOF-based regimen no 4   25,000             18,484,785   7,621,691    711,439     3,701,075    30,518,990   −23,887,819         
   SOF-based regimen no 5   30,000             21,994,785   9,061,691    786,439     3,776,075    35,618,990   −18,787,819         
   SOF-based regimen no 6   35,000             25,504,785   10,501,691   861,439     3,851,075    40,718,990   −13,687,819         
   SOF-based regimen no 7   40,000             29,014,785   11,941,691   936,439     3,926,075    45,818,990   −8,587,819          
   SOF-based regimen no 8   45,000             32,524,785   13,381,691   1,011,439   4,001,075    50,918,990   −3,487,819          
   SOF-based regimen no 9   50,000             36,034,785   14,821,691   1,086,439   4,076,075    56,018,990   1,612,181           
  SOF-based regimen no 10   55,000             39,544,785   16,261,691   1,161,439   4,151,075    61,118,990   6,712,181           

**Abbreviations:** CHC, chronic hepatitis C; HCC, hepatocellular carcinoma; Diff, difference in cost; Dis Progr, disease progression; HCV, hepatitis C virus; HIV, human immunodeficiency virus; SOF, sofosbuvir.

###### 

Results of one-way sensitivity analyses

  Scenario                   Average cost (€)   Base case    Therapy cost −10%   Therapy cost +10%   SVR rates −10%   SVR rates +10%   No of F0--F2 patients −10%   No of F0--F2 patients (CHC) +10%
  -------------------------- ------------------ ------------ ------------------- ------------------- ---------------- ---------------- ---------------------------- ----------------------------------
  Treatment                                                                                                                                                         
   SOF-based regimen no 1    12,000             17.258.990   15.533.091          18.984.889          22.277.980       12.240.000       16.200.306                   18.347.473
   SOF-based regimen no 2    15,000             20.318.990   18.287.091          22.350.889          25.337.980       15.300.000       19.056.306                   21.617.473
   SOF-based regimen no 3    20,000             25.418.990   22.877.091          27.960.889          30.437.980       20.400.000       23.816.306                   27.067.473
   SOF-based regimen no 4    25,000             30.518.990   27.467.091          33.570.889          35.537.980       25.500.000       28.576.306                   32.517.473
   SOF-based regimen no 5    30,000             35.618.990   32.057.091          39.180.889          40.637.980       30.600.000       33.336.306                   37.967.473
   SOF-based regimen no 6    35,000             40.718.990   36.647.091          44.790.889          45.737.980       35.700.000       38.096.306                   43.417.473
   SOF-based regimen no 7    40,000             45.818.990   41.237.091          50.400.889          50.837.980       40.800.000       42.856.306                   48.867.473
   SOF-based regimen no 8    45,000             50.918.990   45.827.091          56.010.889          55.937.980       45.900.000       47.616.306                   54.317.473
   SOF-based regimen no 9    50,000             56.018.990   50.417.091          61.620.889          61.037.980       51.000.000       52.376.306                   59.767.473
   SOF-based regimen no 10   55,000             61.118.990   55.007.091          67.230.889          66.137.980       56.100.000       57.136.306                   65.217.473

**Notes:** All costs are shown in Euros. F0--F2 is relating to hepatic fibrosis (stage of liver disease) (mild to moderate).

**Abbreviations:** CHC, chronic hepatitis C; SOF, sofosbuvir; SVR, sustained virological response.
